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Many common viruses (eg, influenza, rhinoviruses) are
controlled or cleared by an individual’s immune system
with few long-term sequelae. However, certain viral or host
factors—viral type (and subtype), duration of infection, age
at time of acquisition, immunosuppressive conditions or
medications, and duration of the infection—increase the
pathogenicity of viruses.1 In these situations, antiviral or
antiretroviral agents may be prescribed for treatment of ac-
tive disease, prevention, or preemptive therapy.
Because viral replication relies on a host cell for its life
cycle, most antiviral and antiretroviral agents interrupt
the viral replication within the host cell.2 However; inter-
feron augments the host’s immune response and assists
with viral clearing.3 Both mechanisms decrease the clini-
cal manifestations of a virus. 
Herpes Simplex Virus 
Herpes simplex virus (HSV), a double-stranded DNA
virus, exists as 2 subtypes, HSV-1 and HSV-2. Infection
occurs by mucus membrane contact with HSV. Viral par-
ticles are secreted from active lesions and genital secre-
tions of infected individuals. HSV-1 is primarily associat-
ed with infections of the mouth (cold sores), whereas
genital herpes is predominately HSV-2. HSV acquisition
results in lifelong infection that presents as alternating
episodes of painful lesions and asymptomatic periods.
Symptomatic reactivation may occur as a result of local
tissue injury, acute illness, immunosuppression, or fever.4
Acyclovir, valacyclovir, and famciclovir are used in the
management of HSV-1 and HSV-2.4,5
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Objective: To review the pharmacologic properties of and uses for the most commonly prescribed antiviral
agents. 
Data Sources: A MEDLINE/PubMed search (1966-September 2010) was conducted for English-language
articles using the terms HIV, hepatitis, cytomegalovirus (CMV), herpes simplex virus (HSV), antiviral agents,
antiretroviral agent, acyclovir, valganciclovir, valacyclovir, interferon, ribavirin, ritonavir, efavirenz,
zidovudine, darunavir, lopinavir, tenofovir, raltegravir, lamivudine, atazanavir, and emtricitabine. Book
chapters and recent guidelines pertaining to the pathophysiology or pharmacologic properties of antiviral
agents were also reviewed.
Study Selection and Data Extraction: Articles, chapters, and guidelines pertaining to the relevant
pharmacologic agents were collected for review.
Data Synthesis: Viral pathogens affect multiple organs, causing direct and indirect damage by activating an
immune response. Unlike bacterial infections, which can be eradicated from the host system, viral infections
are not curable. Antiviral treatments are prescribed to reduce morbidity and mortality. There are many
antiviral and more than 20 antiretroviral agents currently approved by the FDA. These include acyclovir,
valacyclovir, and famciclovir for HSV; ganciclovir, valganciclovir, foscarnet, and cidofovir for CMV;
interferon and ribavirin for hepatitis; and efavirenz, tenofovir, emtricitabine, atazanavir, darunavir, lopinavir,
ritonavir, raltegravir, zidovudine, and lamivudine as first-line agents for HIV.
Conclusions: Viral illnesses affect a large portion of the population. Given the multitude of drugs available,
pharmacists and pharmacy technicians should be educated about common treatment options. Having a
strong knowledge of commonly prescribed antiviral drugs allows these frontline professionals to make a
significant impact on the quality of care that they provide to their patients and community.
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Acyclovir, an acyclic guanine nucleoside analogue, re-
quires tri-phosphorylation by the thymidine kinase in
HSV, Epstein-Barr virus (EBV), and varicella-zoster virus
(VZV) for activation. Once activated, acyclovir serves as
a competitive irreversible chain terminator of viral DNA
replication. Although most effective for treatment of
HSV-1 and HSV-2, it offers some benefit in VZV and lim-
ited benefit in cytomegalovirus (CMV) suppression.
Acyclovir’s poor oral bioavailability (10-30%) requires
that large doses be administered. Valacyclovir, a prodrug
L-valyl ester, was developed to overcome this limitation.
Valacyclovir is converted to acyclovir by first-pass and
hepatic metabolism, reaching an oral bioavailability of
about 55%. Nonmetabolized acyclovir and any metabo-
lites are eliminated  through the renal system; therefore,
dosing adjustments are necessary for patients with renal
dysfunction. Treatment formulations, doses, and admin-
istration frequencies for FDA-approved indications in vi-
ral conditions are listed in Table 1.6,7
Adverse effects of both acyclovir and valacyclovir in-
clude headaches, nausea, and diarrhea. Central nervous
system (CNS) adverse effects, including lethargy, confu-
sion, delirium, and hallucinations, are occasionally seen in
patients with renal dysfunction and those receiving the in-
travenous formulation.8 Severe or fatal thrombocytopenic
syndromes have been reported in immunocompromised
patients.9 Reversible neurotoxicity has also been reported
with high serum acyclovir levels and is likely associated
with a particular acyclovir metabolite.8 Renal dysfunction,
obstruction, and renal tubular damage as a result of acy-
clovir crystallization have also been reported.
The intravenous formulation should be administered
over 1 hour and accompanied by adequate hydration pre-
and postinfusion as a precaution.10 Both oral formulations
should be taken with plenty of water. Other adverse ef-
fects include local irritation with topical formulations and
rare phlebitis with intravenous extravasation.10,11
Nephrotoxicity may be increased when acyclovir is ad-
ministered with other nephrotoxic drugs or when it is
administered with zidovudine or probenecid, which in-
crease acyclovir concentrations.
Famciclovir, a prodrug of penciclovir, requires meta-
bolism in the gastrointestinal tract, blood, and liver for
conversion to its active form. It is a competitive inhibitor
of viral DNA polymerase and is as effective as acyclovir
against herpes.8 Dosage adjustments are necessary in se-
vere renal dysfunction. Like acyclovir and valacyclovir,
rare adverse effects include headache, nausea, and diar-
rhea. Data on use of famciclovir in pregnancy are limited
but animal studies with very high doses found that the
drug may have mutagenic potential. To date, no drug in-
teractions have been identified.12
Cytomegalovirus
CMV, a DNA virus in the herpes family, is also trans-
mitted by bodily fluids. Acute infection is a result of
mouth-to-mouth transmission (ie, kissing), intimate sex-
ual contact, perinatal transmission, and blood transfu-
sion.1,2 Although 50-80% of chronic adult CMV infections
are asymptomatic, acute exposure often begins as a mild
illness with symptoms of fever, sore throat, swollen
glands, and fatigue.13 Occasionally, CMV complications
occur during the chronic viral carrier state, particularly in
patients with immunosuppressive conditions (eg, HIV,
malignancy, transplant recipients, neonates) or those re-
ceiving immunosuppressive medications. Manifestations
of active viral replication can involve a variety of organs,
including the eyes, lungs, CNS, and digestive tract. The
corresponding symptoms include blindness or visual im-
pairment, pneumonia, digestive tract ulceration,
polyradiculopathies, and coma or seizures in the brain.13
Antiviral agents active against CMV are often prescribed
for immunocompromised persons to prevent or treat
these complications. Ganciclovir, foscarnet, and cidofovir
are all approved for CMV treatment.13
Ganciclovir, a deoxyguanosine analogue, is an irre-
versible DNA-chain terminator. It is extremely active
against CMV because the CMV phosphotransferase has a
greater affinity for ganciclovir than for acyclovir. This affini-
ty, in addition to its longer intracellular half-life, makes gan-
ciclovir the treatment of choice for CMV, as opposed to acy-
clovir. It is prescribed for CMV retinitis, as well as
treatment and prevention of other CMV organ-specific dis-
eases in immunosuppressed or transplant patients.14-16
As a result of ganciclovir’s poor bioavailability (8-9%),
valganciclovir, another L-valyl ester prodrug, was devel-
oped.17 Valganciclovir is converted to ganciclovir in the
intestine and the liver, offering great bioavailability
(60%).8 It also possesses good penetration into the cere-
brospinal fluid and brain tissue. Elimination of this un-
metabolized drug occurs by renal excretion, making re-
nal dosing necessary.
Adverse effects of ganciclovir include reversible
myelosuppression, specifically neutropenia (15-40%) and
thrombocytopenia (5-20%).18 This risk increases 2 weeks
into therapy, but is reversible upon drug discontinuation
or with cell line stimulation administration (ie, granulo-
cyte stimulating factor). Five percent to 15% of patients
also experience CNS adverse effects ranging from
headaches to behavior changes or coma as a result of
CNS penetration.
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Table 1. Antiviral Agents
COMMON ADVERSE
DRUG DOSAGE/FORM STANDARD ADULT DOSE EFFECTS/COMMENTS
Valganciclovira 450-mg tablet, 50-mg/mL CMV retinitis: 900 mg twice daily for 14-21 Diarrhea, nausea, GI disturbances, fever, 
(Valcyte) powder for solution days followed by 900 mg once daily for graft rejection, bone marrow suppression,
small peripheral lesions; in combination birth defects
with intraocular ganciclovir implant for 
sight-threatening lesions
Prevention of CMV infection in solid organ 
transplant: 900 mg once daily started within 
10 days of transplantation and continued for 
100 days after transplantation
Acyclovira 200-mg capsule, 400- Immunocompetent pts.: Nausea, vomiting, diarrhea  
(Zovirax) and 800-mg tablets, Initial genital herpes episode: 400 mg 3 times
200-mg/5-mL oral daily or 200 mg 5 times daily for 7-10 days
suspension, 50-mg/mL Recurrent genital herpes episode: 400 mg by
injection, 100- and mouth 3 times daily for 5 days, 800 mg by
500-mg/vial as powder mouth for 5 days or 800 mg by mouth
for injection, 5% (15-g 3 times daily for 2 days
tube) topical ointment, Herpes zoster: 800 mg by mouth 5 times daily
5% (2- and 5-g tubes) for 7-10 days
topical cream HSV encephalitis: 20 mg/kg iv every 8 h
Immunocompromised pts.:
Herpes or varicella zoster: 10 mg/kg/dose iv
or 500 mg/m2/dose by mouth every 8 h for
7 days
Mucocutaneous HSV:  
5 mg/kg/dose iv every 8 h for 7 days or 400 
mg 5 times daily for 7-14 days
Valacyclovira 500-mg and 1-g caplets Initial genital herpes episode: 1 g by mouth Headache, nausea, abdominal pain
(Valtrex) twice daily for 7-10 days
Recurrent genital herpes episode: 500 mg by 
mouth twice daily for 3 days or 1 g by 
mouth daily
Herpes zoster: 1 g by mouth 3 times daily for 
7 days
Famciclovira (Famvir) 125-, 250-, and 500-mg Herpes labialis (cold sores): 1500 mg as a Headache, nausea, diarrhea
tablets single dose
Immunocompetent pts.:
Initial genital herpes episode: 250 mg by 
mouth 3 times daily for 7-10 days
Recurrent genital herpes episode: 125 mg by 
mouth twice daily for 5 days or 1 g by mouth
twice daily for 1 day
Chronic suppressive therapy: 250 mg by mouth
twice daily
Immunocompromised pts.:
Recurrent genital herpes episode: 500 mg by 
mouth twice daily for 5-10 days
Chronic suppressive therapy: 500 mg by mouth
twice daily
Peginterferon alfa-2a 180-mg/0.5- mL prefilled Chronic hepatitis C: 180 μg injected Flu-like syndrome, nausea, vomiting, diarrhea,
(Pegasys) syringes, 180-μg/mL subcutaneously once weekly in combination worsening of psychosis, psychiatric effects,
solution for injection with ribavirin for 24-48 h insomnia, irritability, cardiovascular effects,
Chronic hepatitis B: 180 μg injected increased risk of stroke or myocardial
subcutaneously for 48 wk infarction, bone marrow suppression; 
contraindicated in pts. with estimated 
creatinine clearance <50 mL/min; not for 
use in pts. with severe hepatic impairment
Ribavirina 200-mg tablets Genotypes 1 and 4: Hemolytic anemia, hypersensitivity reactions,
(Copegus) In combination with peginterferon alfa-2a for headache 
48 wk: weight <75 kg, 1000 mg; weight Pregnancy category X
≥75 kg, 1200 mg Contraindicated in hepatic impairment: 
Genotypes 2 and 3: Child-Pugh classes B and C
In combination with peginterferon alfa-2a
for 24 wk: 800 mg
CMV = cytomegalovirus; GI = gastrointestinal; HSV = herpes simplex virus.
aDose adjustment needed in renal insufficiency.
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When ganciclovir and zidovudine are combined, the
effectiveness of both agents decreases. If used with di-
danosine, the risk of didanosine toxicity is increased.8
Valganciclovir also has major interactions with pro-
benecid, mycophenolate mofetil, phenytoin, entecavir, or
tenofovir.10,19 Concomitant use of ganciclovir with these
agents may enhance the adverse effects of thymine ana-
logues or may potentiate renal problems.12
Foscarnet and cidofovir are also effective against CMV
infections, but are administered by intravenous route
only. Their dose-limiting adverse effects include leukope-
nia and neutropenia with cidofovir and renal impair-
ment with foscarnet.
Hepatitis 
Hepatitis may be caused by hepatitis A, B, C, D, and E
viruses.20 Hepatitis A and E viruses are transmitted by
oral and fecal routes, while hepatitis B virus (HBV), hep-
atitis C virus (HCV), and hepatitis D virus are transmit-
ted by blood and bodily fluids.20 Perinatal transmission
of HBV and HCV are also possible.20
Viral hepatitis exhibits both an acute and chronic dis-
ease course. After acute infection, some patients enter
into a noninfectious phase, referred to as remission.20 Al-
ternatively, others enter into a chronic phase with long-
term inflammation that results in extensive liver damage.
Viral hepatitis is a common cause of liver failure and the
most common cause of hepatocellular carcinoma and liv-
er failure requiring transplantation.20,21 The goal of treat-
ment is to prevent chronic sequelae. 
Therapeutic choices vary depending on the hepatitis
subtype, tolerability of indicated drugs, and treatment re-
sponse. Interferon products, with and without the addi-
tion of ribavirin, are prescribed for use in treatment of
HCV and HBV, respectively.20,21 HBV can also be treated
with oral tenofovir, emtricitabine, or lamivudine. Patients
coinfected with HIV and HBV are often prescribed a
combination of tenofovir and emtricitabine as part of
their antiretroviral regimen.20 These nucleoside ana-
logues are reviewed under antiretroviral agents. 
Peginterferon alfa-2a (PIA2a) mimics the body’s natural
interferon by activating natural proteins that provide an an-
tiviral effect.3 PIA2a binds viral infected cells, stimulating
genes that have many biological effects including inhibiting
viral replication, increasing cellular production, and in-
creasing immune system function. It can be used alone as a
single agent for treatment of HBV or in combination with
ribavirin for the treatment of chronic HCV.3,20 Interferon in-
jection is performed via an intramuscular or a subcuta-
neous route. The attachment of polyethylene glycol slows
absorption and decreases drug clearance, allowing once
weekly dosing. Dosing adjustments are necessary for pegy-
lated interferon in severe renal disease.3
Drugs metabolized by the cytochrome P450 system,
particularly CYP1A2, may be inhibited by interferon.
Theophylline and ribavirin toxicities are of particular
concern, as concentrations are increased.3
PIA2a carries 3 boxed warnings. The first, for psychi-
atric effects, cautions use in patients with a history of sui-
cide or suicidal ideation, homicidal ideation, depression,
relapse of drug addiction, or drug overdose. The second
warns of a risk of infections, which should be ruled out in
the presence of fever. Lastly, autoimmune disorders such
as systemic lupus erythematosus and thyroiditis and is-
chemic disorders such as ischemic colitis and myocardial
infarction may occur.3 Treatment should be discontinued if
liver dysfunction is observed. HBV flares during treatment
are possible. Stopping treatment is warranted with an in-
crease in liver enzymes more than 10 times the upper limit
of normal or if increased bilirubin is noted.3
Transmission risks and the HBV/hepatitis A virus vac-
cination status of sexual partners and household mem-
bers may be assessed. A missed dose of interferon may
be administered within 2 days without interruption in a
patient’s dosing schedule; beyond 2 days, a health-care
provider should be contacted. 
RIBAVIRIN
Ribavirin, a nucleoside analogue, is used in the treat-
ment of HCV and in an aerosolized form to treat respira-
tory syncytial virus in infants. Ribavirin, in combination
with PIA2A, is also indicated for the treatment of chronic
HCV.20 Although its mechanism of action has not been
determined, ribavirin should not be used alone.22
Ribavirin dosing for the treatment of HCV depends
on the patient’s weight and the viral genotype. It has not
been studied in patients with creatinine clearance less
than 50 mL/min; thus, it is not recommended in this
population or in patients with decompensated liver dis-
ease.22
Because ribavirin has only been studied in combina-
tion with PIA2A for safety and efficacy, reported adverse
effects are the result of both agents. Ribavirin’s primary
toxicity is hemolytic anemia (hemoglobin <10 g/dL).
This anemia has been linked with risks of cardiac events
such as heart attacks. Patients should be assessed for car-
diac risk factors prior to and after initiation of riba-
virin.20,22
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Hypersensitivity reactions manifesting as urticaria,
bronchoconstriction, and angioedema are rare (<1%)
with the combination therapy of ribavirin and PIA2A. If
such a reaction is observed, treatment should be stopped
immediately. Ribavirin is also associated with teratogenic
and embryogenic effects.22 A negative pregnancy test
should be obtained before initiating treatment with riba-
virin. Pregnancy should be avoided for at least 6 months
after stopping ribavirin therapy in both the male and fe-
male partner.22
The use of both ribavirin and didanosine increases the
risk of hepatic failure, peripheral neuropathy, pancreati-
tis, and lactic acidosis. Ribavirin also exacerbates anemia
and neutropenia when coadministered with zidovudine
and pancytopenia when used with azathioprine.22
Human Immunodeficiency Virus 
The manifestations of HIV, an RNA virus, are associat-
ed with the destruction of the body’s immune response,
particularly CD4+ cells. As a patient’s cell count declines
(indicating immune system damage), he or she is at in-
creased risk for opportunistic infections, a frequent cause
of death in patients not receiving antiretroviral therapy
(ART). ART may prevent additional damage to vital or-
gans as a result of the inflammatory response to HIV it-
self.23,24
HIV treatment utilizes ART combinations to prevent
the development of viral resistance. Infected individuals
should be initiated on ART when their CD4 cell count is
between 350 and 500 cells/mm3.23,24 Other factors for
which treatment should be initiated can be found in
Table 2.23,24
ART’s effectiveness is assessed by viral load. An effec-
tive treatment regimen will result in an undetectable vi-
ral load (<20 copies/mL), indicating reduced viral repli-
cation. When viral replication is controlled, immune
system recovery should occur. Immune recovery is as-
sessed by measuring the CD4+ cell count every 3-6
months.23,24
An adherence rate of at least 95% to all antiretroviral
agents is the key to treatment success.25 This can be a
challenging goal with a large number of pills, an in-
creased dosing frequency, or intolerable adverse effects.
To increase adherence, many manufacturers have devel-
oped combination pills that incorporate at least 2 or 3
medications or have investigated dosing regimens of re-
duced frequency. There are 6 antiretroviral drug classes.
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Table 3. First-Line Antiretroviral Treatmenta
DRUG CLASS DRUG/DOSE
Nucleoside/nucleotide reverse transcriptase inhibitorsb Tenofovir 300 mg and emtricitabine 200 mg by mouth daily
Nonnucleoside reverse transcriptase inhibitors Efavirenz 600 mg by mouth daily on empty stomach
Protease inhibitors Atazanavir 300 mg/ritonavir 100 mg by mouth daily with food
Darunavir 800 mg/ritonavir 100 mg by mouth daily with food
Integrase strain transfer inhibitors Raltegravir 400 mg by mouth twice daily
aDepartment of Health and Human Services 2009 and International AIDS Society 2010 guidelines.
bIn combination with other first-line drugs from any of the above drug classes.
Table 2. Criteria for Starting Antiretroviral Therapy
DEPARTMENT OF HEALTH AND HUMAN SERVICES GUIDELINES INTERNATIONAL AIDS SOCIETY GUIDELINES 
Should be initiated: Should be initiated: 
AIDS-defining illness or opportunistic infections AIDS-defining illness or opportunistic infections
CD4 cell count <350 cells/mm3 CD4 cell count <350-500 cells/mm3
pregnancy pregnancy
HIV-associated nephropathy CD4 cell count decline >100 per year
treatment for hepatitis B is warranted HIV-1 RNA >100,000 copies/mL
Recommend initiation: Recommend initiation:
CD4 cell count >350-500 cells/mm3 and active HBV or HCV
possibly >500 cells/mm3 active or high risk for cardiovascular disease
Factors to consider: >60 years of age
CD4 cell count decline >100 cells/mm3 per year HIV-associated nephropathy
high viral load >100,000 copies/mL symptomatic primary HIV infection
HIV-serodiscordant couples
Consider initiation:
CD4 count >500 cells/mm3
HBV = hepatitis B virus; HCV = hepatitis C virus.
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First-line treatment agents are shown in Table 3.23,24 Also,
a full list of antiretroviral agents, with doses and adverse
effects, can be found in Table 4.23,24
NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE
INHIBITORS
Nucleoside/nucleotide reverse transcriptase inhibitors
(NRTIs), the backbone of current antiretroviral regimens,
inhibit the production of HIV DNA from RNA. They com-
pete for the use of the reverse transcriptase enzyme that
prevents chain elongation and terminates viral replication.
All NRTIs may be administered without regard to
meals except didanosine, which must be taken on an
empty stomach.23,26 All except stavudine and zidovudine
can be administered once daily.23 Lastly, all NRTIs, with
the exception of abacavir, should be renally adjusted.27
Abacavir has recommendations for dosing in hepatic im-
pairment.23
This class carries a black-box warning for lactic acido-
sis, with risk of hepatic impairment, severe liver enlarge-
ment, and death. Female sex, obesity, and pregnancy in-
crease this risk.23,28 Other adverse effects include fat
redistribution and lipodystrophy, which are primarily as-
sociated with stavudine, didanosine, and zidovudine as
a result of their affinity for mitochondrial DNA poly-
merase.23,29 Although the onset of these physical changes
is gradual, patients eventually exhibit central obesity,
limb atrophy, and, potentially, dorsocervical fat enlarge-
ment.29
Most antiretroviral regimens incorporate either
lamivudine or emtricitabine in combination with teno-
fovir or abacavir.23 Patients coinfected with HBV and
HIV require treatment for both infections. Tenofovir with
either lamivudine or emtricitabine can be used, as they
are active against HBV and HIV.30-33 However, it is impor-
tant to note that patients coinfected with HIV/HBV are
at risk of hepatitis B exacerbation at medication initiation
or upon withdrawal. Monitoring for such manifestations
is warranted.34
Although lamivudine is indicated for treatment of
both HIV and HBV, dosing is different for each disease
state.30,32 HIV dosing is higher, making Epivir-HBV an in-
appropriate choice for coinfected patients. All doses of
lamivudine are generally well tolerated.30
Emtricitabine, in combination with tenofovir, is rec-
ommended as the preferred backbone for HIV-treat-
ment–naïve patients.23 Since emtricitabine and lamivu-
dine are structurally related, patients who develop
resistance to lamivudine also have resistance to emtricit-
abine. For this reason, this combination of NRTIs is not
recommended. Although emtricitabine is active in vivo
and in vitro against HBV, it does not carry FDA approval.
Instead, it is a therapeutic option, in combination with
tenofovir, for the treatment of HBV in HIV patients.23,31,32
Abacavir is available as a coformulation with lamivu-
dine (Epzicom) or with zidovudine and lamivudine
(Trizivir). It possesses a black-box warning for a poten-
tially deadly hypersensitivity reaction. This hypersensi-
tivity reaction manifests as a diffuse skin rash, fever,
chills, malaise, nausea, muscle pain, and shortness of
breath. All patients should be screened for the HLA-
B*5701 allele before an abacavir-containing regimen is
initiated.27 HLA-B*5701 positive individuals should not
receive abacavir due to an increased risk of this reac-
tion.23 If a hypersensitivity reaction is suspected, the pa-
tient should never be rechallenged, as death may occur.
Use of abacavir has also been controversially linked to
the development of myocardial infarctions.34 Thus clini-
cians should weigh the risk versus benefit of use of aba-
cavir in patients who are already at high risk or who
have had a cardiovascular event or those with a viral
load >100,000 copies/mL.35,36
Zidovudine, in combination with lamivudine and
lopinavir/ritonavir twice daily, is indicated for pregnant
patients, as there is significant data on prevention of ma-
ternal to fetal HIV-1 transmission.23,37-40 Common adverse
effects include bone marrow suppression, anemia, and less
often, neutropenia. A complete blood cell count should be
monitored 2-8 weeks postinitiation of zidovudine, then ev-
ery 3-6 months.23 Myopathy, lactic acidosis, and hepatotox-
icity have also been reported. In such cases, treatment
should be discontinued under medical supervision. Pa-
tients should contact their provider to report any seizure,
weight loss, loss of appetite, or weight gain.39
Didanosine in combination with efavirenz and emtricit-
abine or lamivudine is considered an acceptable regimen
in treatment-naïve patients only.23 Didanosine and
emtricitabine should not be used with atazanavir due to
inferior response.41 Didanosine carries a black-box warn-
ing for pancreatitis, which occurs more frequently at
higher doses.26 Other adverse effects include optic neuri-
tis and retinal changes; a routine eye exam while on di-
danosine therapy is recommended. Peripheral neuropa-
thy that manifests as numbness, leg pains or tingling,
and portal hypertension has also been reported. This
may warrant the discontinuation of didanosine.26
Adverse effects associated with stavudine are exten-
sive and include pancreatitis and peripheral neuropathy.
Fatal and nonfatal pancreatitis has been reported when
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stavudine is used with didanosine, resulting in a black-
box warning against the use of this combination.42 Zi-
dovudine inhibits stavudine metabolism, leading to drug
accumulation and increasing toxicity; this combination is
contraindicated.40 The use of stavudine in any first-line
combination is not encouraged.23,24
Tenofovir is a preferred treatment for HIV and HBV
coinfection.23,24,31 Tenofovir in combination with emtri-
citabine is the preferred NRTI for treatment-naïve pa-
tients.23,24 This combination is also coformulated with
efavirenz, providing potent virologic suppression.43,44
Although generally well tolerated, tenofovir possesses
a black-box warning for HBV exacerbation with treat-
ment discontinuation.31 Another adverse event is bone
loss45; however, the long-term effect of tenofovir use on
bone health and the risk of fractures is unknown.45 Fan-
coni syndrome—acute renal failure and kidney injury,
with reduction in phosphate level— has also been associ-
ated with tenofovir use.46 Its use with other nephrotoxic
agents or in patients with preexisting renal disease
should be avoided, if possible.23,46
Tenofovir use with other antiretroviral agents should
be assessed.23,24 When used in combination with didano-
sine, tenofovir increases didanosine toxicity. Didanosine
dose reduction or discontinuation is recommended to re-
duce the incidence of pancreatitis and neuropathy.
Atazanavir increases tenofovir concentrations, while
tenofovir reduces atazanavir concentrations. Patients on
tenofovir should be monitored for nephrotoxicity, and ri-
tonavir should be added to enhance the effect of
atazanavir. Lopinavir/ritonavir also increases tenofovir
concentration.44 Monitoring of renal function is always
recommended.31,44
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Nonnucleoside reverse transcriptase inhibitors
(NNRTIs) bind to the nonactive site of the reverse tran-
scriptase enzyme, interrupting viral protein synthesis at
the HIV binding site. All NNRTIs are metabolized by the
liver and inhibit or induce cytochrome P450 system en-
zymes. Their long half-lives allow once- or twice-daily
dosing. Potential adverse effects of this class of drugs are
hepatotoxicity and rash. Unfortunately, poor adherence
to these agents can result in cross-resistance between
efavirenz and nevirapine.18 Etravirine may still have
some activity in such cases and is therefore recommend-
ed as a second-line agent, in combination with a protease
inhibitor (PI)–containing regimen.23,24
Efavirenz, a preferred agent, is recommended for use
in conjunction with 2 NRTIs, preferably tenofovir and
emtricitabine.23,24 This triple-drug combination pill
(Atripla) can be taken once daily, improving patient ad-
herence. CNS effects include vivid dreams, confusion,
dizziness, and sedation. These effects are worse in the first
2-4 weeks of therapy. To reduce these effects, efavirenz-
containing regimens should be taken on an empty stom-
ach, just prior to bedtime.47 Moreover, in a clinical trial,
26% of patients developed a rash compared with 17% in
the placebo arm. Most rashes resolved within the first 2
weeks of use. Less than 0.1% of rashes progressed to a se-
vere form, Stevens-Johnson syndrome, in which blister-
ing and shedding of the outer layers of skin occur.44
Efavirenz is contraindicated in women of childbearing
age who are not using 2 forms of birth control or those
considering pregnancy within 12 weeks.47 Case reports
on efavirenz exposure during the first trimester of preg-
nancy have described neural tube defects; however, a
meta-analysis and a systematic review of outcomes of an
observational cohort concluded that a larger sample size
is needed to prove the relationship between neural tube
defects in the first trimester of pregnancy and efavirenz
exposure.48 Meanwhile, efavirenz remains classified as
pregnancy category D.18,47 Lastly, multiple interactions
with this drug class should prompt a review for potential
interactions between any NNRTI and other hepatically
metabolized medications.
Nevirapine is contraindicated for use in men whose
CD4 count is more than 400 cells/mm3 and in women
with a CD4 cell count more than 250 cells/mm3. Use in
individuals with CD4 cell counts above these cut offs or
in persons with underlying hepatic disease (ie, hepatitis)
increases the risk of rash, hepatotoxicity, and death.49
Etravirine has a greater barrier to resistance. It too pos-
sesses the risk for erythema multiforme (Stevens-Johnson
syndrome). Twice-daily administration with food is rec-
ommended to achieve appropriate concentrations.50
PROTEASE INHIBITORS
PIs prevent the protease enzyme cleavage of provirus
particles into active viral components. Although this
class is extremely potent, tolerability, adverse effects, pill
burden, and drug interactions remain a challenge. Admin-
istration requirements vary, but most should be taken with
food to improve tolerability. All PIs are hepatically metabo-
lized by and inhibit or induce the cytochrome P450 en-
zymes, making drug interactions a common concern. Inter-
actions may decrease ART effectiveness or increase
potential toxicities of other medications. Class adverse ef-
fects include gastrointestinal upset, hyperglycemia, hyper-
lipidemia, hepatotoxicity, cardiovascular events, and in-
creased bleeding in hemophiliacs. The extent of these
effects varies among agents.23,24
Ritonavir was one of the first PIs introduced. However,
due to poor tolerability (ie, diarrhea and vomiting) and an
extensive adverse effect profile, this drug is no longer a pri-
mary treatment agent.23,24 Instead, ritonavir 100 mg or 200
mg is currently recommended for use in combination
with most PIs and fewer other antiretroviral agents to
boost concentrations. Ritonavir inhibits drug metabo-
lism, reducing dosing frequency and pill burden of other
agents.23
In 2010, a new tablet formulation was FDA approved.
This formulation does not require refrigeration, which is
a requirement of the capsule formulation.51,52 The newer
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tablet does require administration with food to achieve
appropriate concentrations.51,52
Kaletra, a combination PI, incorporates ritonavir with
lopinavir to provide effective drug concentrations. Dos-
ing for treatment-naïve patients is once daily, as opposed
to twice daily for treatment-experienced patients with
drug resistance.52 Despite gastrointestinal upset and in-
creases in cholesterol, particularly triglycerides, it re-
mained a preferred agent for years. In 2009, Kaletra was
noted to increase the risk of PR and QT interval prolon-
gation.53 It has been reclassified as an alternative treat-
ment agent in treatment-naïve patients.23 It remains a
preferred agent in pregnancy, in which case it is adminis-
tered twice daily.52
Atazanavir offers improved tolerability with a good
lipid profile.23,54 Its once-daily dosing, with or without ri-
tonavir, increases adherence. Boosting with ritonavir is
preferred and required with tenofovir use.23 Administra-
tion with food is required to increase absorption and lim-
it variability in drug concentrations.55 Use of antacids, H2
antagonists, or proton pump inhibitors can decrease the
effectiveness of atazanavir. Assessment of administration
times and doses is important as they may result in treat-
ment failure because of insufficient atazanavir levels.55
Adverse effects of hyperbilirubinemia, occasionally re-
sulting in mild symptoms of jaundice or scleral icterus,
are possible although not pathogenic. Less common ad-
verse events include a mild-to-moderate rash, prolonga-
tion of PR intervals, and rare cases of nephrolithiasis at
increased concentrations.55
Darunavir in combination with ritonavir offers good
tolerability, once-daily dosing, and potency.56-58 Treatment-
experienced patients currently receive twice-daily dos-
ing.23 Administration with food is required.56-58 Darunavir
is generally well tolerated except that a skin rash may oc-
cur in about 10% of patients as a result of its sulfa moiety.
Occasionally this rash is severe, with erythema multiforme
and Stevens-Johnson syndrome occurring. Caution should
be used in patients with HBV or HBC, as darunavir use
can result in liver enzyme increases.56-58
Dosing and potential adverse effects of nonpreferred
PIs, fosamprenavir, indinavir, nelfinavir, tipranavir, and
saquinavir may be found in Table 4.59-63
INTEGRASE STRAND TRANSFER INHIBITOR
Raltegravir blocks the integrase enzyme’s ability to in-
corporate newly manufactured HIV DNA into the host’s
cell DNA. Although a preferred treatment agent with
tenofovir and emtricitabine, it can also be used in combi-
nation with other effective antiretroviral agents for treat-
ment-experienced patients.23,24 Dosing is twice daily
without food restrictions. Potential drug interactions are
limited, as raltegravir is not metabolized nor is it an in-
ducer or inhibitor of the cytochrome P450 system, but in-
stead is metabolized by glucuronidation.64,65
It was well tolerated in clinical trials, with limited gas-
trointestinal upset compared with placebo, and did not
increase cholesterol levels.64,65 Rare creatinine kinase ele-
vations associated with myopathy and rhabdomyolysis
have been reported with raltegravir, particularly when
used in combination with other drugs that have the same
risk factors.66
Dosing and common adverse effects of less commonly
used agents, namely enfuvirtide, a fusion inhibitor, and
maraviroc, a CCR5 antagonist, can be found in Table 4.67,68
Summary
Viral infections (ie, HIV, HSV, HCV, and HBV) are of-
ten sexually transmitted. The Centers for Disease Control
and Prevention and the Department of Health and Hu-
man Services offer easily accessible detailed guidelines
that help with the management of hepatitis, sexually
transmitted diseases, and HIV. Although expert clini-
cians are often the primary health-care professionals in-
volved in the management of viral infections, pharmacy
technicians are on the front line with pharmacists during
the dispensing of these antiviral agents. Being knowl-
edgeable about commonly prescribed antiviral medica-
tions and related diseases improves the pharmacist’s
identification of drug interactions, management of ad-
verse effects, appropriate dosing, and key counseling
points. 
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